BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25658463)

  • 21. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.
    Zhang X; Wan G; Mlotshwa S; Vance V; Berger FG; Chen H; Lu X
    Cancer Res; 2010 Sep; 70(18):7176-86. PubMed ID: 20668064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Wip1 phosphatase and Mdm2: cracking the "Wip" on p53 stability.
    Lu X; Nguyen TA; Zhang X; Donehower LA
    Cell Cycle; 2008 Jan; 7(2):164-8. PubMed ID: 18333294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HDM2 promotes WIP1-mediated medulloblastoma growth.
    Buss MC; Read TA; Schniederjan MJ; Gandhi K; Castellino RC
    Neuro Oncol; 2012 Apr; 14(4):440-58. PubMed ID: 22379189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
    Long X; Lin XJ
    J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
    Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
    Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
    Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
    J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas.
    Wang P; Rao J; Yang H; Zhao H; Yang L
    J Surg Oncol; 2011 Nov; 104(6):679-84. PubMed ID: 21695702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inhibition of WIP1 phosphatase accelerates the depletion of primordial follicles.
    Zhou S; Xi Y; Chen Y; Wu T; Yan W; Li M; Wu M; Luo A; Shen W; Xiang T; Wang S
    Reprod Biomed Online; 2021 Aug; 43(2):161-171. PubMed ID: 34210610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic WIP1 phosphatase attenuates the DNA damage response and sensitizes p53 mutant Jurkat cells to apoptosis.
    Eren MK; Kartal NB; Pilevneli H
    Oncol Lett; 2021 Jun; 21(6):479. PubMed ID: 33968195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
    Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
    Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
    Ogasawara S; Kiyota Y; Chuman Y; Kowata A; Yoshimura F; Tanino K; Kamada R; Sakaguchi K
    Bioorg Med Chem; 2015 Oct; 23(19):6246-9. PubMed ID: 26358280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xL ratio.
    Goloudina AR; Mazur SJ; Appella E; Garrido C; Demidov ON
    Cell Cycle; 2012 May; 11(10):1883-7. PubMed ID: 22544321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA damage signaling induced by the G-quadruplex ligand 12459 is modulated by PPM1D/WIP1 phosphatase.
    Douarre C; Mergui X; Sidibe A; Gomez D; Alberti P; Mailliet P; Trentesaux C; Riou JF
    Nucleic Acids Res; 2013 Apr; 41(6):3588-99. PubMed ID: 23396447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wip1 deficiency impairs haematopoietic stem cell function via p53 and mTORC1 pathways.
    Chen Z; Yi W; Morita Y; Wang H; Cong Y; Liu JP; Xiao Z; Rudolph KL; Cheng T; Ju Z
    Nat Commun; 2015 Apr; 6():6808. PubMed ID: 25879755
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Milosevic J; Treis D; Fransson S; Gallo-Oller G; Sveinbjörnsson B; Eissler N; Tanino K; Sakaguchi K; Martinsson T; Wickström M; Kogner P; Johnsen JI
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
    Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
    J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.
    Crescenzi E; Raia Z; Pacifico F; Mellone S; Moscato F; Palumbo G; Leonardi A
    J Biol Chem; 2013 Jun; 288(23):16212-16224. PubMed ID: 23612976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
    Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
    Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides: A new series of small molecule inhibitors for Wip1 phosphatase.
    Robello M; Zheng H; Saha M; George Rosenker KM; Debnath S; Kumar JP; Tagad HD; Mazur SJ; Appella E; Appella DH
    Eur J Med Chem; 2022 Dec; 243():114763. PubMed ID: 36179402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1.
    Yoda A; Xu XZ; Onishi N; Toyoshima K; Fujimoto H; Kato N; Oishi I; Kondo T; Minami Y
    J Biol Chem; 2006 Aug; 281(34):24847-62. PubMed ID: 16798742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.